LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Savara Inc

Затворен

СекторЗдравеопазване

5.09 3.25

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.86

Максимум

5.26

Ключови измерители

By Trading Economics

Приходи

-5M

-37M

Служители

70

EBITDA

-5.5M

-39M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+126.57% upside

Дивиденти

By Acuity

Следващи печалби

12.08.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-12M

1B

Предишно отваряне

1.84

Предишно затваряне

5.09

Настроения в новините

By Acuity

25%

75%

56 / 344 Класиране в Healthcare

Savara Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.06.2026 г., 23:36 ч. UTC

Correction to Oracle Reports Higher 4Q Profit Article

10.06.2026 г., 23:19 ч. UTC

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10.06.2026 г., 23:09 ч. UTC

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10.06.2026 г., 23:04 ч. UTC

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10.06.2026 г., 20:44 ч. UTC

Caterpillar Raises Quarterly Dividend 8%

10.06.2026 г., 23:49 ч. UTC

Elliott: Northern Star Should Take No Options Off The Table

10.06.2026 г., 23:48 ч. UTC

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10.06.2026 г., 23:48 ч. UTC

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10.06.2026 г., 23:47 ч. UTC

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10.06.2026 г., 23:47 ч. UTC

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10.06.2026 г., 23:46 ч. UTC

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10.06.2026 г., 23:38 ч. UTC

Global Equities Roundup: Market Talk

10.06.2026 г., 23:38 ч. UTC

Global Forex and Fixed Income Roundup: Market Talk

10.06.2026 г., 23:38 ч. UTC

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10.06.2026 г., 23:32 ч. UTC

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10.06.2026 г., 23:20 ч. UTC

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10.06.2026 г., 22:05 ч. UTC

Correction to Bank of Canada Stays on Hold Market Talk

10.06.2026 г., 21:57 ч. UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10.06.2026 г., 21:52 ч. UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10.06.2026 г., 21:35 ч. UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10.06.2026 г., 21:22 ч. UTC

Oracle Stock Slides on Increased Capital Spending -- WSJ

10.06.2026 г., 20:50 ч. UTC

Tech, Media & Telecom Roundup: Market Talk

10.06.2026 г., 20:50 ч. UTC

Financial Services Roundup: Market Talk

10.06.2026 г., 20:50 ч. UTC

Basic Materials Roundup: Market Talk

10.06.2026 г., 20:50 ч. UTC

Health Care Roundup: Market Talk

10.06.2026 г., 20:39 ч. UTC

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10.06.2026 г., 20:34 ч. UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10.06.2026 г., 20:33 ч. UTC

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10.06.2026 г., 20:33 ч. UTC

Global Equities Roundup: Market Talk

10.06.2026 г., 20:33 ч. UTC

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Savara Inc Прогноза

Ценова цел

By TipRanks

126.57% нагоре

12-месечна прогноза

Среден 11.17 USD  126.57%

Висок 16 USD

Нисък 9 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Savara Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

6

Купи

0

Задържане

0

Продай

Настроение

By Acuity

56 / 344 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
help-icon Live chat